Radioligand Therapy (RLT) in France

This article outlines how France reorganised itself to meet the growing demand for radioligand therapy (RLT) in patients with prostate cancer following VISION trial's success in 2021. A national RLT network has progressively established itself as a key structure on which administrative bodies, scientific societies, policymakers, and industry partners can rely. By identifying existing gaps between supply and demand, the RLT network is now positioned to support nuclear medicine departments in implementing RLT, thereby expanding patient access to this innovative therapeutic approach and responding to the increasing demand in prostate cancer as well as other cancers.